Skip to content


  • Meeting abstract
  • Open Access

HTLV-1 modulates alternative splicing in CD4+ T cells in vivo

  • 1,
  • 1,
  • 2,
  • 3,
  • 3,
  • 4,
  • 1 and
  • 1Email author
Retrovirology20118 (Suppl 1) :A168

  • Published:


  • Ingenuity Pathway Analysis
  • Intron Retention
  • Exon Expression
  • Transcriptional Dysregulation
  • Exclusive Exon

Transcriptional dysregulation is the hallmark of HTLV-1 infected cells yet the impact of HTLV-1 on alternative splicing (AS) remains unknown. Given that about 95% of genes are spliced, we investigated the exon expression profiling of CD4+ T-cell clones obtained by limited-dilution cloning of PBMC deriving from HTLV-1 carriers. Overall, 12 infected clones clustering in infected, uninfected, PHA-stimulated or unstimulated CD4+ T cells were compared for exon RNA content using Exon Chip Human microarray. The splicing index method was used to identify differentially expressed exons in paired comparisons. The exon content of 558 genes differed between infected and uninfected CD4+ T cells. Of these, only 76 genes were found differentially expressed at the whole transcriptional level. 360 exon events (185/558 genes) could be manually annotated in FASTDB database and corresponded to exon skipping (59 genes), mutually exclusive exons (151), 5’ splice site (5’SS) (4), 3’SS (3), internal exon deletion (23), and intron retention (15). Some of these are already validated by exon specific RT-PCR experiments that are in progress. Exon-based hierarchical clustering analysis identified alternative exons associated with HTLV-1 infection and/or PHA stimulation. Ingenuity Pathway Analysis revealed new AS-based pathways of gene deregulation irrespective of whole transcriptional deregulation. These corresponded to hitherto unknown deregulation pattern of cell cycling and DNA damage response. Thus, HTLV-1 infection possesses a transcription-independent but AS-based signature that unmasks numerous new putative leukemogenic pathways.

Authors’ Affiliations

Oncovirologie et Biotherapies, UMR5239 CNRS/ENS Lyon/UCBL/HCL, Hopital Pierre Benite, Lyon, France
Oncovirologie et Biothérapies, Centre Léon Bérard, Lyon, France
ProfileXpert, Neurobiotec Service, Bron, 69500, France
Institut National de Santé et de Recherche Médicale U590, Centre Léon Bérard, Lyon, France


© Thenoz et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.